|Updates from the National Cancer Institute|
|Clinical Trials News|
|NCI-funded TMIST Study Compares 2-D and 3-D Mammography for Finding Breast Cancers|
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of digital mammography for breast cancer screening, is now open for enrollment.
|Video—Patient Safety in Clinical Trials|
Patient safety is of paramount importance in cancer clinical trials. This new video discusses how patient rights and safety are protected in clinical research.
|CAR T-Cell Therapy Approved for Some Children and Young Adults with Leukemia|
FDA has approved tisagenlecleucel (Kymriah™), a type of immunotherapy called CAR T-cell therapy, for some children and young adults with advanced acute lymphoblastic leukemia (ALL). The approval was based on a multicenter clinical trial involving 63 children and young adults with B-cell ALL that had relapsed or resisted treatment.
|FDA Approves Olaparib as Maintenance Therapy for Recurrent Ovarian Cancer|
FDA has granted full approval to olaparib tablets (Lynparza®) as maintenance treatment for patients with recurrent ovarian cancer who are having partial or complete responses to platinum-based chemotherapy. The approval is based on findings from two randomized clinical trials involving patients with recurrent ovarian cancer.
|.||Find NCI-Supported Clinical Trials|
Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
|Clinical Trials Information for Patients and Caregivers|
|Deciding to Take Part in a Clinical Trial|
This page discusses things to consider when you are deciding whether to take part in a clinical trial.
|Questions to Ask Your Doctor about Treatment Clinical Trials|
Taking part in a cancer treatment clinical trial is a big decision. This page presents a list of questions you may want to ask your doctor about before deciding to participate in a clinical trial.
|NCI-Supported Clinical Trials that Are Recruiting Patients|
|Lutetium Lu 177-DOTA-TATE in Treating Patients with Metastatic Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery|
This phase 2 trial studies how well lutetium Lu 177-DOTA-TATE works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body and cannot be removed by surgery.
|T-Cell Immunotherapy and Aldesleukin in Treating Patients with Vulvar High-Grade Intraepithelial Lesions that are HPV-16 Positive and Cannot Be Removed by Surgery|
This phase 1 trial studies the safety of T-cell immunotherapy and aldesleukin in treating patients with vulvar high-grade intraepithelial lesions (HSIL) that are human papilloma virus-16 (HPV-16) positive and which surgery has failed to control. T cells will be harvested from the patient’s blood and genetically engineered to express a receptor that recognizes the E6 protein on cells infected with HPV-16. The genetically engineered T cells will then be put back into the patient.
|Anti-KRAS G12V Peripheral Blood Lymphocytes, Chemotherapy, and Aldesleukin in Treating Patients with KRAS G12V-Positive and HLA-A*1101-Positive Cancer|
This phase 1/2 trial will assess the safety and efficacy of anti-KRAS G12V peripheral blood lymphocytes, chemotherapy, and aldesleukin, and see how well they work in treating patients with KRAS G12V-positive and HLA-A*1101-positive cancer. T cells will be harvested from the patient’s blood and genetically engineered to express a receptor that recognizes G12V-mutated variant of KRAS. The genetically engineered T cells will then be put back into the patient.
Los ángeles a veces también se pueden equivocar
Hace 8 horas